Business Segments · Asset impairments and accelerated depreciation
North American Pharmaceutical — Asset impairments and accelerated depreciation
McKesson North American Pharmaceutical — Asset impairments and accelerated depreciation remained flat by 0.0% to $1.00M in Q4 2025 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ3 2024
Last reportedQ4 2025
How to read this metric
An increase signals potential overvaluation of assets or a strategic pivot that renders existing infrastructure obsolete.
Detailed definition
This metric represents non-cash charges taken when the carrying value of assets in the North American Pharmaceutical seg...
Peer comparison
Standard non-cash impairment charge reported by peers during periods of asset rationalization.
Metric ID:
mck_segment_north_american_pharmaceutical_asset_impairments_and_accelerated_depreciationHistorical Data
4 periods
| Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|
| Value | $63.00M | $1.00M | $1.00M | $1.00M |
| QoQ Change | — | -98.4% | +0.0% | +0.0% |
| YoY Change | — | — | -98.4% | +0.0% |
Range$1.00M – $63.00M
Avg YoY Growth-49.2%
Median YoY Growth-49.2%
Current Streak2 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's north american pharmaceutical — asset impairments and accelerated depreciation?
- McKesson (MCK) reported north american pharmaceutical — asset impairments and accelerated depreciation of $1.00M in Q4 2025.
- What does north american pharmaceutical — asset impairments and accelerated depreciation mean?
- The reduction in value of assets or accelerated depreciation charges within the North American Pharmaceutical segment due to business changes.